<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table2" position="float"><label>Table 2.</label><caption><title>Summary by dataset of the prevalence and distribution of the genetic markers of resistance and resistance phenotypes tested.</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variant</th><th/><th colspan="3">Genetic</th><th colspan="2">Phenotypic</th></tr><tr><th/><th>RplD G70D</th><th>23S rRNA C2611T (2&#8211;4 alleles)</th><th><italic>penA</italic> XXXIV</th><th>CRO-RS (&#8805;0.12 &#956;g/mL)</th><th>CFX-R (&gt;0.25 &#956;g/mL)</th></tr></thead><tbody><tr><td>Drug</td><td/><td>AZM (<xref ref-type="bibr" rid="bib31">Grad et al., 2016</xref>)</td><td>AZM (<xref ref-type="bibr" rid="bib49">Lk et al., 2002</xref>)</td><td>ESCs (<xref ref-type="bibr" rid="bib30">Grad et al., 2014</xref>)</td><td>N/A</td><td>N/A</td></tr><tr><td rowspan="5">Prevalence of variant in dataset</td><td valign="top">1</td><td>10.04%<sup>*</sup></td><td>0.11%</td><td>5.25%</td><td>1.47%</td><td>0.11%</td></tr><tr><td valign="top">2</td><td>1.14%</td><td>1.24%</td><td>1.69%</td><td>0%</td><td>0%</td></tr><tr><td valign="top">3</td><td>2.47%</td><td>0.95%</td><td>15.68%<sup>*</sup></td><td>1.04%</td><td>0.76%</td></tr><tr><td valign="top">4</td><td>11.07%<sup>*</sup></td><td>1.23%</td><td>0.41%</td><td>6.56%</td><td>8.20%</td></tr><tr><td valign="top">5</td><td>0.75%</td><td>0.50%</td><td>2.26%</td><td>0.25%</td><td>0%</td></tr><tr><td rowspan="5">Phylogenetic D statistic for variant in dataset</td><td valign="top">1</td><td>&#8722;0.18</td><td>17.50</td><td>&#8722;0.29</td><td>N/A</td><td>N/A</td></tr><tr><td valign="top">2</td><td>&#8722;0.10</td><td>0.46</td><td>&#8722;0.24</td><td>N/A</td><td>N/A</td></tr><tr><td valign="top">3</td><td>0.05</td><td>0.30</td><td>&#8722;0.20</td><td>N/A</td><td>N/A</td></tr><tr><td valign="top">4</td><td>&#8722;0.16</td><td>1.83</td><td>1.81</td><td>N/A</td><td>N/A</td></tr><tr><td valign="top">5</td><td>0.83</td><td>1.12</td><td>&#8722;0.15</td><td>N/A</td><td>N/A</td></tr></tbody></table><table-wrap-foot><fn><p>*Given the&#160;&gt;10% prevalence of RplD G70D in datasets 1 and 4 and <italic>penA</italic> XXXIV in dataset 3, these variants were excluded from sampling simulations.</p><p>AZM, azithromycin; ESC, extended-spectrum cephalosporin; CRO-RS, ceftriaxone reduced susceptibility; CFX-R, cefixime resistance.</p></fn></table-wrap-foot></table-wrap>